Novos fármacos no tratamento da tuberculose
Cezar, Michelle Caileaux; Guerra, Renata Leborato; Conde, Marcus Barreto.
Pulmäo RJ
; 18(1): 23-26, 2009.
Artigo em Português | LILACS | ID: lil-548979
Documentos relacionados
Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs <i>In Vitro</i>.
Proteomic Landscape of a Drug-Tolerant Persister Subpopulation of <i>Mycobacterium tuberculosis</i>.
QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents.
Autophagy Induction as a Host-Directed Therapeutic Strategy against <i>Mycobacterium tuberculosis</i> Infection.
Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents.
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.
[Evaluation of Mycobacterium tuberculosis Culture and Drug Susceptibility Test Results and the Distribution of Nontuberculosis Mycobacteria from the Clinical Specimens].
Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.